In vitro and in vivo inhibitory effect evaluation of cyclooxygenase-2 inhibitors, antisense cyclooxygenase-2 cDNA, and their combination on the growth of human bladder cancer cells

Biomedicine and Pharmacotherapy

Volumn 63, Issue 3, 2009, Pages 241-248

  Qin, Jun ^a   Yuan, Jianlin ^a   Li, Ling ^b   Liu, Heliang ^a   Qin, Rongliang ^a   Qin, Weijun ^a   Chen, Baoqi ^a   Wang, He ^a   Wu, Kaichun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

COX 2 antisense cDNA; COX 2 inhibitor; Therapeutic effect

Indexed keywords

ANTISENSE CYCLOOXYGENASE 2 DNA; CELECOXIB; COMPLEMENTARY DNA; CYCLOOXYGENASE 2; INDOMETACIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL; CANCER GROWTH; CANCER MODEL; CELL COUNT; CELL CYCLE G1 PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DNA, ANTISENSE; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INDOMETHACIN; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PYRAZOLES; SULFONAMIDES; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 61349185227     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2008.04.007     Document Type: Article

References (25)

1. Garcia J.A., and Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol 24 (2006) 5545-5551
2. Black P.C., Brown G.A., Grossman H.B., and Dinney C.P. Neoadjuvant chemotherapy for bladder cancer. World J Urol 24 (2006) 531-542
3. Bamias A., Tiliakos I., Karali M.D., and Dimopoulos M.A. Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann Oncol 17 (2006) 553-561
4. Pruthi R.S., Derksen E., Gaston K., and Wallen E.M. Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology 64 (2004) 637-642
5. Qin J., Wu K.C., Yao L.P., and Shao G.X. Occurrence, biological behavior and prognosis of bladder carcinoma: relationship between cyclooxygenase-2 expression and microvascular density. [in Chinese]. Chin J Clin Rehab 8 (2004) 6402-6405
6. Wild P.J., Kunz-Schughart L.A., Stoehr R., Burger M., Blaszyk H., Simon R., et al. High-throughput tissue microarray analysis of COX-2 expression in urinary bladder cancer. Int J Oncol 27 (2005) 385-391
7. Wülfing C., Eltze E., von Struensee D., Wülfing P., Hertle L., and Piechota H. Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol 45 (2004) 46-52
8. Grubbs C.J., Lubet R.A., Koki A.T., Leahy K.M., Masferrer J.L., Steele V.E., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 60 (2000) 5599-5602
9. Sheehy O.E., Zhao S.Z., Raymoundo A.L., Miller B., Aprikian A.G., and Lelorier J. Celecoxib associated with reduced risk of superficial bladder cancer (SBC) recurrence. (abstract). Proc Am Soc Clin Oncol 22 (2003) 383
10. Fitzgerald G.A. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2 (2003) 879-890
11. Solomon S.D., McMurray J.J., Pfeffer M.A., Wittes J., Fowler R., Finn P., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352 (2005) 1071-1080
12. Hull M.A. Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?. Eur J Cancer 41 (2005) 1854-1863
13. Dandekar A.S., and Lokeshwar B.L. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer cells significantly slows tumor growth and improves efficacy of chemotherapeutic drugs. Clin Cancer Res 10 (2004) 8037-8047
14. Chen Q., Shinohara N., Abe T., Watanabe T., Nonomura K., and Koyanagi T. Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 108 (2004) 825-832
15. Qin J., Wu K.C., Wang H., Chen B.Q., Yao L.P., and Shao G.X. The inhibition of malignant phenotypes of human bladder cancer cells by anti-sense nucleic acid of cyclooxygenase-2. [in Chinese]. Chin J Urol 27 (2006) 235-238
16. Palayoor S.T., Arayankalayil M.J., Shoaibi A., and Coleman C.N. Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2. Clin Cancer Res 11 (2005) 6980-6986
17. Narayanan B.A., Narayanan N.K., Davis L., and Nargi D. RNA interference-mediated cyclooxygenase-2 inhibition prevents prostate cancer cell growth and induces differentiation: modulation of neuronal protein synaptophysin, cyclin D1, and androgen receptor. Mol Cancer Ther 5 (2006) 1117-1125
18. Potera C. Antisense-down, but not out. Nat Biotechnol 25 (2007) 497-499
19. Erovic B.M., Woegerbauer M., Pammer J., Selzer E., Grasl M., and Thurnher D. Strong evidence for up-regulation of cyclooxygenase-1 in head and neck cancer. Eur J Clin Invest 38 (2008) 61-66
20. Patel M.I., Subbaramaiah K., Du B., Chang M., Yang P., Newman R.A., et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2-independent mechanism. Clin Cancer Res 11 (2005) 1999-2007
21. Mohammed S.I., Dhawan D., Abraham S., Snyder P.W., Waters D.J., Craig B.A., et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 5 (2006) 329-336
22. Gee J., Lee I.L., Jendiroba D., Fischer S.M., Grossman H.B., and Sabichi A.L. Selective cyclooxygenase-2 inhibitors inhibit growth and induce apoptosis of bladder cancer. Oncol Rep 15 (2006) 471-477
23. Kashfi K., and Rigas B. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. Biochem Pharmacol 70 (2005) 969-986
24. Bock J.M., Menon S.G., Sinclair L.L., Bedford N.S., Goswami P.C., Domann F.E., et al. Celecoxib toxicity is cell cycle phase specific. Cancer Res 67 (2007) 3801-3808
25. de Groot D.J.A., de Vries E.G.E., Groen H.J.M., and de Jong S. Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol 61 (2007) 52-69